Patents by Inventor Thomas Bourne

Thomas Bourne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150405
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: October 23, 2023
    Publication date: May 9, 2024
    Inventors: Chengzao SUN, Brian Troy FREDERICK, Sandeep SOMANI, Gregory Thomas BOURNE, Raymond PATCH, Ashok BHANDARI, Raffaele INGENITO, Roberto COSTANTE, Danila BRANCA, Elisabetta BIANCHI
  • Publication number: 20240132558
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: January 13, 2023
    Publication date: April 25, 2024
    Inventors: Ashok BHANDARI, Gregory Thomas BOURNE
  • Publication number: 20240066131
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 28, 2021
    Publication date: February 29, 2024
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Jie ZHANG, Brian Troy FREDERICK, Mark Leslie SMYTHE
  • Patent number: 11884748
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: January 30, 2024
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Publication number: 20240016895
    Abstract: The disclosure provides compositions and methods for the treatment and/or prevention of sickle cell disease.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 18, 2024
    Inventors: David Y. LIU, Gregory Thomas BOURNE, Roopa TARANATH, Li ZHAO
  • Publication number: 20240018189
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 18, 2024
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Jie ZHANG, Brian Troy FREDERICK, Mark Leslie SMYTHE
  • Patent number: 11845808
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: December 19, 2023
    Assignees: Janssen Biotech, Inc., Protagonist Therapeutics, Inc.
    Inventors: Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Gregory Thomas Bourne, Raymond Patch, Ashok Bhandari
  • Patent number: 11807674
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: November 7, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20230295259
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 28, 2021
    Publication date: September 21, 2023
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Jie Zhang, Brian Troy Frederick, Mark Leslie Smythe, Roopa Taranath
  • Patent number: 11753443
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 12, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Brian Troy Frederick, Jie Zhang, Adam Stephenson, Mark Leslie Smythe, Roopa Taranath, David Liu
  • Publication number: 20230129095
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: January 14, 2021
    Publication date: April 27, 2023
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok BHANDARI, Brian Troy FREDERICK, Tran Trung TRAN, Gregory Thomas BOURNE
  • Publication number: 20220372099
    Abstract: The present invention provides hepcidin analogues, and related pharmaceutical compositions and use thereof in treating polycythemia vera.
    Type: Application
    Filed: September 3, 2020
    Publication date: November 24, 2022
    Inventors: David Y. LIU, Gregory Thomas BOURNE, Roopa TARANATH, Suneel Kumar GUPTA, Nishit Bachulal MODI
  • Publication number: 20220348626
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: November 16, 2020
    Publication date: November 3, 2022
    Inventors: Mark Leslie SMYTHE, Gregory Thomas BOURNE, Simone VINK, Brian Troy FREDERICK, Praveen MADALA, Anne Pernille TOFTENG SHELTON, Jacob Ulrik FOG
  • Patent number: 11472842
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: October 18, 2022
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
  • Publication number: 20210363185
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Application
    Filed: January 28, 2021
    Publication date: November 25, 2021
    Inventors: Ashok BHANDARI, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Publication number: 20210261622
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: January 14, 2021
    Publication date: August 26, 2021
    Inventors: Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Gregory Thomas Bourne, Raymond Patch, Ashok Bhandari, Raffaele Ingenito, Roberto Costante, Danila Branca, Elisabetta Bianchi
  • Publication number: 20210147483
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: October 1, 2020
    Publication date: May 20, 2021
    Inventors: Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
  • Patent number: 10941183
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 9, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Publication number: 20210061872
    Abstract: The present invention provides hepcidin analogues, and related pharmaceutical compositions and use thereof in treating polycythemia vera.
    Type: Application
    Filed: September 3, 2020
    Publication date: March 4, 2021
    Inventors: David Y. Liu, Gregory Thomas Bourne, Roopa Taranath, Suneel Kumar Gupta, Nishit Bachulal Modi
  • Publication number: 20200361992
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: February 8, 2019
    Publication date: November 19, 2020
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Brian Troy FREDERICK, Jie ZHANG, Adam STEPHENSON, Mark Leslie SMYTHE, Roopa TARANATH, David LIU